OYE Therapeutics has been authorized to initiate clinical development of its OYE-101 caffeine injection after the U.S. FDA cleared its Investigational New Drug applications. OYE-101 is a novel ...

Researchers hope to discover unknown psychedelic compounds inside Australia’s floral emblem to treat intractable mental ...

The FDA designation expands the drug's potential patient pool tenfold, to an estimated 13 million Americans who consider suicide annually. Clinical trials demonstrated rapid and statistically ...

ARBLI ™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. ARBLI ™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, ...

Lipocine expects trial data to support a 505(b)(2) new drug application submission for LPCN 1154 in 2026.

Leaders of the D.S.M., the world’s most influential psychiatric manual, have been split for more than five years over whether ...

Lipocine ( (LPCN)) has shared an announcement. On January 20, 2026, Lipocine announced it has completed enrollment and dosing of 90 patients in its Phase 3 clinical trial of LPCN 1154, an oral ...

When it comes to the market for cognitive and energy support, experts note that the market’s sustained growth speaks to the ...

The FDA has cleared Crown Point, Ind.-based OYE Therapeutics’ investigational new drug application for OYE-101, clearing the company to begin clinical development. OYE-101 is an intravenous caffeine ...

Company highlights accelerating access and revenue growth for ARBLI and confirms REZENOPY launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million Ou ...

Hisar: Mental health problems tend to worsen with seasonal changes, particularly during the monsoon and autumn months, ...

BOCA RATON, FL, UNITED STATES, January 21, 2026 /EINPresswire.com/ -- As interest in holistic health solutions surges ...